东阳光药拟实施H股全流通

Core Viewpoint - Dongyangguang Pharmaceutical (600673) announced the approval of a proposal to convert 251 million domestic shares held by shareholders into H-shares, representing approximately 43.59% of the company's total issued share capital as of the announcement date [1] Group 1 - The company's board of directors has reviewed and approved the proposal for the conversion of domestic shares into H-shares [1] - The number of domestic shares intended for conversion into H-shares is subject to approval from the China Securities Regulatory Commission and the Hong Kong Stock Exchange [1]